These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 9000189

  • 1. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens.
    Caubet JF, Tosteson TD, Dong EW, Naylon EM, Whiting GW, Ernstoff MS, Ross SD.
    Urology; 1997 Jan; 49(1):71-8. PubMed ID: 9000189
    [Abstract] [Full Text] [Related]

  • 2. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide.
    Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD.
    Prostate Cancer Prostatic Dis; 1999 Jan; 2(1):4-8. PubMed ID: 12496859
    [Abstract] [Full Text] [Related]

  • 3. [First line therapy in the treatment of metastatic prostate cancer].
    Sakai H, Kanetake H.
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
    [Abstract] [Full Text] [Related]

  • 4. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials.
    Bria E, Cuppone F, Giannarelli D, Milella M, Ruggeri EM, Sperduti I, Pinnarò P, Terzoli E, Cognetti F, Carlini P.
    Cancer; 2009 Aug 01; 115(15):3446-56. PubMed ID: 19484790
    [Abstract] [Full Text] [Related]

  • 5. Maximal androgen blockade for advanced prostate cancer.
    Klotz L.
    Best Pract Res Clin Endocrinol Metab; 2008 Apr 01; 22(2):331-40. PubMed ID: 18471790
    [Abstract] [Full Text] [Related]

  • 6. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K, Lehnert M, Stettner H, Hubmer G.
    Eur Urol; 1997 Apr 01; 32 Suppl 3():81-5. PubMed ID: 9267791
    [Abstract] [Full Text] [Related]

  • 7. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
    Bennett CL, Matchar D, McCrory D, McLeod DG, Crawford ED, Hillner BE.
    Cancer; 1996 May 01; 77(9):1854-61. PubMed ID: 8646685
    [Abstract] [Full Text] [Related]

  • 8. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
    Moreau JP, Delavault P, Blumberg J.
    Clin Ther; 2006 Oct 01; 28(10):1485-508. PubMed ID: 17157109
    [Abstract] [Full Text] [Related]

  • 9. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.
    J Urol; 2008 Sep 01; 180(3):921-7. PubMed ID: 18635218
    [Abstract] [Full Text] [Related]

  • 10. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
    Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, Chamberlain M, Carroll K, Melezinek I.
    J Urol; 2000 Nov 01; 164(5):1579-82. PubMed ID: 11025708
    [Abstract] [Full Text] [Related]

  • 11. Complete androgen blockade for prostate cancer: what went wrong?
    Laufer M, Denmeade SR, Sinibaldi VJ, Carducci MA, Eisenberger MA.
    J Urol; 2000 Jul 01; 164(1):3-9. PubMed ID: 10840412
    [Abstract] [Full Text] [Related]

  • 12. Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences.
    Collette L, Studer UE, Schröder FH, Denis LJ, Sylvester RJ.
    Prostate; 2001 Jun 15; 48(1):29-39. PubMed ID: 11391684
    [Abstract] [Full Text] [Related]

  • 13. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR, CaPSURE Investigators.
    Cancer; 2006 Apr 15; 106(8):1708-14. PubMed ID: 16544313
    [Abstract] [Full Text] [Related]

  • 14. Endocrine treatment of prostate cancer.
    Tammela T.
    J Steroid Biochem Mol Biol; 2004 Nov 15; 92(4):287-95. PubMed ID: 15663992
    [Abstract] [Full Text] [Related]

  • 15. Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review.
    Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, Wullich B, Meerpohl JJ.
    BJU Int; 2015 Jul 15; 116(1):30-6. PubMed ID: 25523493
    [Abstract] [Full Text] [Related]

  • 16. [Meta-analysis of the Italian studies on short-term effects of air pollution].
    Biggeri A, Bellini P, Terracini B, Italian MISA Group.
    Epidemiol Prev; 2001 Jul 15; 25(2 Suppl):1-71. PubMed ID: 11515188
    [Abstract] [Full Text] [Related]

  • 17. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
    Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, Wilt T, Ziegler K.
    Evid Rep Technol Assess (Summ); 1999 May 15; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
    [Abstract] [Full Text] [Related]

  • 18. [Usefulness and positioning of MAB therapy for prostate cancer].
    Akaza H, Chodak GW, Hirao Y.
    Gan To Kagaku Ryoho; 2005 Oct 15; 32(10):1507-20. PubMed ID: 16227758
    [Abstract] [Full Text] [Related]

  • 19. An oncology perspective on the benefits and cost of combined androgen blockade in advanced prostate cancer.
    Aprikian AG, Fleshner N, Langleben A, Hames J.
    Can J Urol; 2003 Oct 15; 10(5):1986-94. PubMed ID: 14633326
    [Abstract] [Full Text] [Related]

  • 20. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, Kirkali Z, Calais da Silva FM, Robertson C.
    Eur Urol; 2009 Jun 15; 55(6):1269-77. PubMed ID: 19249153
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.